Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction.

Pfizer, Moderna and AstraZeneca are producing the leading COVID-19 vaccine candidates. How effective are they in helping end the pandemic? Hotspots ranked Start the day smarter ☀️ Funniest cap ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.

Pfizer and AstraZeneca Debate: When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn ...

Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15% on Monday after U.S. pharmaceutical firm Pfizer said it offered to buy the company.

Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds ...

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

AstraZeneca’s vaccine, developed with Oxford University, is also much easier to distribute because it can be stored at higher temperatures than the Pfizer alternative.

Pfizer, AstraZeneca and others ask US Supreme Court to bar Iraq terrorism funding claims. ... The Pfizer logo is seen at their world headquarters in New York April 28, 2014.

AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent ...

Pfizer Inc. was turned down twice by fellow drugmaker AstraZeneca PLC, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders ...